Safety and Efficacy of Alefacept, Efalizumab, Etanercept, and Infliximab in Treating Moderate to Severe Psoriasis: A Meta-Analysis of Randomized Controlled Trials

Simple item page
dc.contributor.advisorJohn Licciardone
dc.contributor.committeeMemberRoberto Cardarelli
dc.contributor.committeeMemberRichard Virgilio
dc.creatorBrimhall, Angela K.
dc.date.accessioned2019-08-22T21:49:35Z
dc.date.available2019-08-22T21:49:35Z
dc.date.issued2007-05-03
dc.date.submitted2013-11-25T17:34:14-08:00
dc.description.abstractBrimhall, Angela K., Master of Science, Clinical Research and Academic Medicine, May 19, 2007, Safety and Efficacy of Alefacept, Efalizumab, Etanercept, and Infliximab in Treating Moderate to Severe Plaque Psoriasis: A Meta-Analysis of Randomized Controlled Trials. Pages=41, Tables=3, Figures=9, Bibliography=61 titles. To evaluate and compare efficacy and safety of biological agents in the treatment of plaque psoriasis, data was identified through four parallel systematic reviews. Randomized, controlled, double-blind, monotherapy trials of alefacept, efalizumab, etanercept and infliximab were selected. Sixteen studies comprising 7,931 patients met inclusion criteria. Efficacy was measured by pooled relative risk (RR) and number needed to treat (NNT) of PASI 75 achievement as compared to placebo. Each biological agent was efficacious (P [less than] .001); however, there was a graded response for achievement of PASI 75. The risk of one or more adverse event was increased in the alefacept, efalizumab, and infliximab groups compared to placebo.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/20.500.12503/29610
dc.language.isoen
dc.provenance.legacyDownloads0
dc.subjectChemicals and Drugs
dc.subjectDermatology
dc.subjectDiseases
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.subjectOther Pharmacy and Pharmaceutical Sciences
dc.subjectPharmacology
dc.subjectPharmacy and Pharmaceutical Sciences
dc.subjectSkin and Connective Tissue Diseases
dc.subjectModerate to severe
dc.subjectplaque psoriasis
dc.subjectsafety
dc.subjectbiological agents
dc.subjectsystematic review
dc.subjectpooled relative risk
dc.subjectnumber needed to treat
dc.subjectrisk
dc.subjectmonotherapy trial
dc.subjectalefacept
dc.subjectefalizumab
dc.subjectetanercept
dc.subjectinfliximab
dc.titleSafety and Efficacy of Alefacept, Efalizumab, Etanercept, and Infliximab in Treating Moderate to Severe Psoriasis: A Meta-Analysis of Randomized Controlled Trials
dc.typeThesis
dc.type.materialtext
thesis.degree.departmentGraduate School of Biomedical Sciences
thesis.degree.disciplineClinical Research and Education: Osteopathic Manipulative Medicine
thesis.degree.grantorUniversity of North Texas Health Science Center at Fort Worth
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Brimhall_SafetyAndEfficacyOf.pdf
Size:
14.31 MB
Format:
Adobe Portable Document Format
Download

Collections

School of Biomedical Sciences
Theses and Dissertations